hugel’s purpose is to create more smiles in the mirror
WE BELIEVE THAT QUALITY AND AFFORDABILITY CAN COEXIST—AND THAT EVERYONE SHOULD BE ABLE TO INVEST IN THEIR OWN
beauty journey.
beauty journey.
WHO IS HUGEL AESTHETICS?
Hugel Aesthetics is a joint venture between two world leaders within the aesthetics industry—South Korea's Hugel, Inc. and Austria’s Croma-Pharma GmbH. Headquartered in the US we also have offices in Canada and Australia with future operations planned for New Zealand.
GLOBAL PRESENCE
THE FUTURE OF AESTHETICS
Not actual product*
INNOVATION
RESEARCH & DEVELOPMENT
MANUFACTURING
HUGEL AESTHETICS PRODUCTS
Our lineup of products is designed to provide medical professionals and patients around the world with a growing portfolio of advanced treatment options.
PRODUCT
IMPORTANT SAFETY INFORMATION
Letybo*
(
*Talk to your healthcare provider to learn more.
†Individual results may vary. Talk to an Aesthetic Medical Professional to determine if Saypha® is right for you.
HUGEL HIGHLIGHTS
Hugel has sold product in over 50 different countries—and now we are bringing our innovation to the world’s largest aesthetics markets.
Small Bio-Venture
2001
Hugel, Inc. is established in Seoul, South Korea
2010
Hugel, Inc. launches its first product, domestic name Botulax®, in the South Korean market
2014
Croma-Pharma, founded in 1976, makes a strategic decision to focus solely on minimally invasive aesthetics medicine
Market Leader in South Korea
2016
Botulax® becomes the market leader in South Korea and has maintained the position ever since
Market Leader in South Korea
2018
Hugel, Inc. enters South Korea's hyaluronic acid (HA) filler market with THE CHAEUM, currently one of the world’s leading HA brands
Global Player
2018
Hugel Aesthetics, a joint venture between Hugel, Inc. and Austria's Croma-Pharma GmbH, is formed to bring our high-quality aesthetics solutions to the US, Canada, Australia and New Zealand
Global Player
2020
Hugel, Inc.’s letibotulinumtoxinA formulation (export name Letybo®) is the first South Korean brand to obtain approval from China, one of the world's largest aesthetics markets
2022
Hugel Aesthetics expands its presence in Canada and Australia with the respective approvals of Letybo® (letibotulinumtoxinA for injection)* and bolsters its filler portfolio with the approval of Volume Plus
2022
Letybo® (letibotulinumtoxinA for injection) receives marketing approval in Europe